STALEVO 150 pharmaceutical API fine chemical sources

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical	⤷ Get Started Free	2023-05-5H00538	⤷ Get Started Free
RR Scientific	⤷ Get Started Free	R6267804	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 2, 2025

Introduction

STALEVO 150, a prominent pharmaceutical formulation primarily used for Parkinson’s disease management, combines four active ingredients: levodopa, carbidopa, entacapone, and opicapone. The therapeutic efficacy of STALEVO 150 hinges on the quality and supply of its constituent APIs. Ensuring a reliable, high-quality API source is crucial for pharmaceutical manufacturers aiming to produce consistent, regulatory-compliant formulations. This report explores the global landscape of bulk API suppliers for each component of STALEVO 150, highlighting key manufacturing regions, prominent suppliers, and market dynamics shaping the supply chain.

1. Levodopa API Supply Sources

Global Production and Leading Suppliers

Levodopa remains one of the most extensively produced dopaminergic agents. The supply is concentrated predominantly in regions with advanced pharmaceutical manufacturing infrastructure, notably India, China, and European Union countries.

India:
Indian pharmaceutical firms such as Sun Pharma, Cipla, and Jubilant Life Sciences are leading producers of levodopa. These companies leverage established fermentation and chemical synthesis routes to manufacture high-quality APIs compliant with international standards.
China:
Chinese manufacturers, including Zhejiang NHU Co. and North China Pharmaceutical Group (NCPC), have ramped up capacities due to the large domestic demand and export markets. They supply both bulk API and finished dosages.
Europe:
European firms like Evonik Industries and Merck KGaA produce levodopa for niche applications and high-grade APIs, often exporting globally to meet stringent quality requirements.

Manufacturing Challenges and Quality Considerations

Levodopa synthesis involves complex chemical processes that require rigorous quality controls to ensure purity. The key is sourcing APIs from manufacturers adhering to Good Manufacturing Practices (GMP) and possessing relevant certifications, such as ISO or EU-GMP.

2. Carbidopa API Sources

Leading Markets and Suppliers

Carbidopa, a decarboxylase inhibitor, is primarily supplied by major pharmaceutical scale-ups in India and China.

Indian Manufacturers:
Cadila Healthcare, Sun Pharma, and Dr. Reddy’s Laboratories offer GMP-certified carbidopa APIs. Indian firms dominate due to cost competitiveness and established export channels.
Chinese Suppliers:
Companies such as Jiangsu Hengrui Medicine and Zhejiang Huahai Pharmaceutical have expanded their API portfolios to include carbidopa, leveraging mature chemical synthesis technologies.
Global Certification:
Suppliers with FDA, EMA, or PMDA approvals are preferred by multinational pharmaceutical companies to ensure international compliance.

3. Entacapone API Sourcing

Market Landscape

Entacapone, a COMT inhibitor, is a more recent addition to active ingredients used alongside levodopa for Parkinson’s treatment.

Major Producers:
Large biotech and chemical firms in India (e.g., Sun Pharma, Cadila) and China (e.g., Jiangsu Hengrui Medicine) manufacture entacapone APIs for export.
Supply Chain Dynamics:
The API for entacapone needs high stereoselectivity and purity standards, making supplier validation critical. Notably, some suppliers have obtained WHO-GMP certifications, increasing their credibility.

4. Opicapone API Suppliers

Emerging Market Sources

Opicapone, a newer reversible COMT inhibitor, has an emerging supply chain due to recent regulatory approvals in Europe and Japan.

Manufacturers:
Large Chinese pharmaceutical companies like Zhejiang Hisun Pharmaceutical and Hunan Jiahua Pharmaceutical are reportedly producing opicapone APIs for regional markets.
Supply Concerns:
Since opicapone is newer, supply stability depends on market acceptance and regulatory approvals, prompting some companies to develop in-house capacity or forge strategic alliances.

Market Trends and Supply Chain Considerations

Regulatory Compliance: Suppliers aligned with cGMP, ISO, and other international standards dominate the market, ensuring API quality consistency.
Geopolitical Factors: Trade policies and tariffs influence sourcing decisions. For instance, recent US-China trade tensions and European regulations urge diversification strategies.
Supply Chain Resilience: Manufacturers increasingly source from multiple vendors, safeguarding against geopolitical disruptions or manufacturing shortfalls.
Cost and Lead Time Considerations: Indian and Chinese suppliers tend to offer competitive pricing with shorter lead times, though quality verification remains essential.

Conclusion

The API sourcing landscape for STALEVO 150 involves a diverse array of suppliers primarily from India and China, supported by select European API producers. Ensuring GMP-compliant, high-purity APIs remains critical for the manufacturing of this complex medication. Strategic supplier validation, diversification, and adherence to regulatory standards underpin the effective procurement of these APIs.

Key Takeaways

Leading API Suppliers: Indian companies such as Sun Pharma, Cipla, and Dr. Reddy’s dominate the levo/dopa and carbidopa markets; Chinese firms lead in entacapone and emerging opicapone supplies.
Quality Assurance: Manufacturers must prioritize sourcing from suppliers with full GMP, ISO, and international regulatory certifications to meet stringent quality requirements.
Market Dynamics: Cost competitiveness, geopolitical stability, and regulatory landscapes significantly influence API source decisions.
Supply Chain Diversification: To mitigate risks, pharmaceutical companies should diversify API suppliers across regions, ensuring continuity and compliance.
Emerging APIs: Opicapone’s newer market presence requires ongoing monitoring of supply stability and new supplier development.

FAQs

1. What are the main challenges in sourcing APIs for STALEVO 150?
Challenges include maintaining high purity standards, navigating regulatory compliance across regions, supply chain disruptions, and managing costs without compromising quality.

2. Which regions are the primary suppliers of APIs used in STALEVO 150?
India and China are the predominant sources, with European manufacturers supplying specialty APIs like levodopa for high-end markets.

3. How important is regulatory certification for API suppliers?
Very important; certifications like GMP, ISO, and adherence to international regulations ensure API quality, safety, and market acceptance.

4. Are there alternatives to traditional API sources for STALEVO 150 components?
Yes, some pharmaceutical companies develop in-house synthesis capabilities or partner with contract manufacturing organizations (CMOs) to secure supply.

5. How might geopolitical factors impact future API sourcing for STALEVO 150?
Trade tensions, tariffs, and export restrictions could disrupt supply chains, emphasizing the need for diversified sourcing strategies.

References

[1] Pharma Intelligence. "Global API Market Report," 2022.
[2] U.S. Food & Drug Administration. "Guidance for Industry: Good Manufacturing Practices," 2021.
[3] Indian Pharmaceutical Alliance. "Overview of API Manufacturing Capabilities," 2022.
[4] Chinese Pharmacopoeia. "Standards for API Quality," 2021.
[5] European Medicines Agency. "API Certification and Quality Standards," 2022.

Bulk Pharmaceutical API Sources for STALEVO 150